|MDACC Study No:||2013-0324 (clinicaltrials.gov NCT No: NCT01928537)|
|Title:||Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Blasts Progressing On or After Azacitidine or Decitabine|
|Principal Investigator:||Guillermo Garcia-Manero|
|Treatment Agent:||RIGOSERTIB SODIUM (ON 01910.Na)|
|Study Description:||Patients with MDS often need blood cell transfusions to prevent diseases like |
anemia (low red blood cell counts), bleeding, and/or serious infections.
However, these transfusions can lead to collections of abnormal cells, called
blasts, which can put you at a higher risk for developing leukemia.
The goal of this clinical research study is to learn if rigosertib can help to
control MDS in patients with an unusual number of blasts. The safety of this
drug will also be studied.